Literature DB >> 23416790

Thermal sensitivity as a measure of spontaneous morphine withdrawal in mice.

Rebecca E Balter1, Linda A Dykstra.   

Abstract

INTRODUCTION: Opioid withdrawal syndrome is a critical component of opioid abuse and consists of a wide array of symptoms including increases in pain sensitivity (hyperalgesia). A reliable preclinical model of hyperalgesia during opioid withdrawal is needed to evaluate possible interventions to alleviate withdrawal. The following study describes a method for assessing increases in thermal sensitivity on the hotplate in a mouse model of spontaneous morphine withdrawal.
METHODS: C57BL/6J mice received 5.5days of 30, 56, or 100mg/kg morphine or saline (s.c., twice daily). In Experiment I, thermal sensitivity data were collected at baseline and at 8, 24, 32, 48h and 1week following the final injection. Thermal sensitivity was assessed by examining latency to respond on a hotplate across a range of temperatures (50, 52, 54, and 56°C). In Experiment II, 0.01mg/kg buprenorphine was administered 30min prior to each testing session during the withdrawal period. In Experiment III, jumping during a 30min period was assessed at baseline and at 0, 8, 24, 32, and 48h following the final morphine injection.
RESULTS: During the withdrawal period, thermal sensitivity increased significantly in all morphine-treated mice as compared to saline-treated mice. Thermal sensitivity was greater in mice treated with 56mg/kg morphine compared to 30mg/kg and peaked earlier than in mice treated with 100mg/kg (32h v 1wk). The increase in thermal sensitivity following 56mg/kg morphine was attenuated by a dose of buprenorphine that did not produce antinociception alone (i.e., 0.01mg/kg). In general, the results of the jumping experiment paralleled those obtained in Experiment I. DISCUSSION: Response latency on the hotplate is a reliable and sensitive measure of spontaneous morphine withdrawal in mice, making it an ideal behavior for assessing the potential of medications and environmental interventions to alleviate opioid withdrawal.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23416790      PMCID: PMC3631460          DOI: 10.1016/j.vascn.2013.02.003

Source DB:  PubMed          Journal:  J Pharmacol Toxicol Methods        ISSN: 1056-8719            Impact factor:   1.950


  30 in total

1.  Induction of opioid-dependent individuals onto buprenorphine and buprenorphine/naloxone soluble-films.

Authors:  E C Strain; J A Harrison; G E Bigelow
Journal:  Clin Pharmacol Ther       Date:  2011-01-26       Impact factor: 6.875

2.  Lipoxin A4 analog attenuates morphine antinociceptive tolerance, withdrawal-induced hyperalgesia, and glial reaction and cytokine expression in the spinal cord of rat.

Authors:  H Jin; Y H Li; J S Xu; G Q Guo; D L Chen; Y Bo
Journal:  Neuroscience       Date:  2012-02-14       Impact factor: 3.590

3.  Statement of the American Society Of Addiction Medicine Consensus Panel on the use of buprenorphine in office-based treatment of opioid addiction.

Authors:  Mark L Kraus; Daniel P Alford; Margaret M Kotz; Petros Levounis; Todd W Mandell; Marjorie Meyer; Edwin A Salsitz; Norman Wetterau; Stephen A Wyatt
Journal:  J Addict Med       Date:  2011-12       Impact factor: 3.702

Review 4.  Sex differences in thermal nociception and morphine antinociception in rodents depend on genotype.

Authors:  J S Mogil; E J Chesler; S G Wilson; J M Juraska; W F Sternberg
Journal:  Neurosci Biobehav Rev       Date:  2000-05       Impact factor: 8.989

5.  Opioid-induced hyperalgesia and incisional pain.

Authors:  X Li; M S Angst; J D Clark
Journal:  Anesth Analg       Date:  2001-07       Impact factor: 5.108

6.  Morphine in combination with metabotropic glutamate receptor antagonists on schedule-controlled responding and thermal nociception.

Authors:  Bradford D Fischer; Eric I Zimmerman; Mitchell J Picker; Linda A Dykstra
Journal:  J Pharmacol Exp Ther       Date:  2007-11-02       Impact factor: 4.030

7.  Qualitative differences between C57BL/6J and DBA/2J mice in morphine potentiation of brain stimulation reward and intravenous self-administration.

Authors:  Greg I Elmer; Jeanne O Pieper; Lindsey R Hamilton; Roy A Wise
Journal:  Psychopharmacology (Berl)       Date:  2009-12-15       Impact factor: 4.530

8.  The effect of environmental factors on morphine withdrawal in C57BL/6J mice: running wheel access and group housing.

Authors:  Rebecca E Balter; Linda A Dykstra
Journal:  Psychopharmacology (Berl)       Date:  2012-08-19       Impact factor: 4.530

9.  Concurrent validation of the Clinical Opiate Withdrawal Scale (COWS) and single-item indices against the Clinical Institute Narcotic Assessment (CINA) opioid withdrawal instrument.

Authors:  D Andrew Tompkins; George E Bigelow; Joseph A Harrison; Rolley E Johnson; Paul J Fudala; Eric C Strain
Journal:  Drug Alcohol Depend       Date:  2009-08-03       Impact factor: 4.492

10.  Naloxone rapidly evokes endogenous kappa opioid receptor-mediated hyperalgesia in naïve mice pretreated briefly with GM1 ganglioside or in chronic morphine-dependent mice.

Authors:  Stanley M Crain; Ke-Fei Shen
Journal:  Brain Res       Date:  2007-07-14       Impact factor: 3.252

View more
  6 in total

1.  [Approach to creating early diabetic peripheral neuropathy rat model].

Authors:  J He; G H Yuan; J Q Zhang; X H Guo
Journal:  Beijing Da Xue Xue Bao Yi Xue Ban       Date:  2019-12-18

2.  Structure-based discovery of opioid analgesics with reduced side effects.

Authors:  Aashish Manglik; Henry Lin; Dipendra K Aryal; John D McCorvy; Daniela Dengler; Gregory Corder; Anat Levit; Ralf C Kling; Viachaslau Bernat; Harald Hübner; Xi-Ping Huang; Maria F Sassano; Patrick M Giguère; Stefan Löber; Grégory Scherrer; Brian K Kobilka; Peter Gmeiner; Bryan L Roth; Brian K Shoichet
Journal:  Nature       Date:  2016-08-17       Impact factor: 49.962

3.  The G protein-biased κ-opioid receptor agonist RB-64 is analgesic with a unique spectrum of activities in vivo.

Authors:  Kate L White; J Elliott Robinson; Hu Zhu; Jeffrey F DiBerto; Prabhakar R Polepally; Jordan K Zjawiony; David E Nichols; C J Malanga; Bryan L Roth
Journal:  J Pharmacol Exp Ther       Date:  2014-10-15       Impact factor: 4.030

4.  Use of home cage wheel running to assess the behavioural effects of administering a mu/delta opioid receptor heterodimer antagonist for spontaneous morphine withdrawal in the rat.

Authors:  Michael M Morgan; Danielle L Peecher; John M Streicher
Journal:  Behav Brain Res       Date:  2020-10-06       Impact factor: 3.332

5.  Kratom Alkaloids, Natural and Semi-Synthetic, Show Less Physical Dependence and Ameliorate Opioid Withdrawal.

Authors:  Lisa L Wilson; Soumen Chakraborty; Shainnel O Eans; Thomas J Cirino; Heather M Stacy; Chloe A Simons; Rajendra Uprety; Susruta Majumdar; Jay P McLaughlin
Journal:  Cell Mol Neurobiol       Date:  2021-01-12       Impact factor: 4.231

6.  Correlation of TGN-020 with the analgesic effects via ERK pathway activation after chronic constriction injury.

Authors:  Liang Zhao; Dan Li; Nan Liu; Lu Liu; Zhuo Zhang; Chao Gao; Hitoshi Kawano; Fang-Yuan Zhou; Hong-Peng Li
Journal:  Mol Pain       Date:  2018 Jan-Dec       Impact factor: 3.395

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.